Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01JPL
|
||||
| Former ID |
DNCL003819
|
||||
| Drug Name |
VEGFR3 Monoclonal Antibody
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1] | ||
| Company |
Lilly
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 3 | Target Info | Modulator | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| NetPath Pathway | TNFalpha Signaling Pathway | ||||
| Pathway Interaction Database | VEGF and VEGFR signaling network | ||||
| VEGFR3 signaling in lymphatic endothelium | |||||
| Reactome | VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Signaling by VEGF | ||||
| References | |||||
| REF 1 | J Clin Oncol 29: 2011 (suppl, abstr TPS150). | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.